ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

J. A. Ledermann; X. Matias-Guiu; F. Amant; N. Concin; B. Davidson; C. Fotopoulou; A. González-Martin; C. Gourley; A. Leary; D. Lorusso; S. Banerjee; L. Chiva; D. Cibula; N. Colombo; S. Croce; A. G. Eriksson; C. Falandry; D. Fischerova; P. Harter; F. Joly; C. Lazaro; C. Lok; S. Mahner; F. Marmé; C. Marth; W. G. McCluggage; I. A. McNeish; P. Morice; S. Nicum; A. Oaknin; J. A. Pérez-Fidalgo; S. Pignata; P. T. Ramirez; I. Ray-Coquard; I. Romero; G. Scambia; J. Sehouli; R. Shapira-Frommer; S. Sundar; D. S.P. Tan; C. Taskiran; W. J. van Driel; I. Vergote; F. Planchamp; C. Sessa; A. Fagotti

doi:10.1016/j.annonc.2023.11.015

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

J. A. Ledermann, X. Matias-Guiu, F. Amant, N. Concin, B. Davidson, C. Fotopoulou, A. González-Martin, C. Gourley, A. Leary, D. Lorusso, S. Banerjee, L. Chiva, D. Cibula, N. Colombo, S. Croce, A. G. Eriksson, C. Falandry, D. Fischerova, P. Harter, F. JolyC. Lazaro, C. Lok, S. Mahner, F. Marmé, C. Marth, W. G. McCluggage, I. A. McNeish, P. Morice, S. Nicum, A. Oaknin, J. A. Pérez-Fidalgo, S. Pignata, P. T. Ramirez, I. Ray-Coquard, I. Romero, G. Scambia, J. Sehouli, R. Shapira-Frommer, S. Sundar, D. S.P. Tan, C. Taskiran, W. J. van Driel, I. Vergote, F. Planchamp, C. Sessa, A. Fagotti

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

45 Citations (Scopus)

Résumé

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

langue originale	Anglais
Pages (de - à)	248-266
Nombre de pages	19
journal	Annals of Oncology
Volume	35
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.annonc.2023.11.015
état	Publié - 1 mars 2024

Accès au document

10.1016/j.annonc.2023.11.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., ... Fagotti, A. (2024). ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Annals of Oncology, 35(3), 248-266. https://doi.org/10.1016/j.annonc.2023.11.015

@article{658bd901509b47cf9ce8d776fcee3e3e,

title = "ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease",

abstract = "The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.",

keywords = "chemotherapy, maintenance treatment, molecular biology, ovarian cancer, pathology, surgery",

author = "Ledermann, {J. A.} and X. Matias-Guiu and F. Amant and N. Concin and B. Davidson and C. Fotopoulou and A. Gonz{\'a}lez-Martin and C. Gourley and A. Leary and D. Lorusso and S. Banerjee and L. Chiva and D. Cibula and N. Colombo and S. Croce and Eriksson, {A. G.} and C. Falandry and D. Fischerova and P. Harter and F. Joly and C. Lazaro and C. Lok and S. Mahner and F. Marm{\'e} and C. Marth and McCluggage, {W. G.} and McNeish, {I. A.} and P. Morice and S. Nicum and A. Oaknin and P{\'e}rez-Fidalgo, {J. A.} and S. Pignata and Ramirez, {P. T.} and I. Ray-Coquard and I. Romero and G. Scambia and J. Sehouli and R. Shapira-Frommer and S. Sundar and Tan, {D. S.P.} and C. Taskiran and {van Driel}, {W. J.} and I. Vergote and F. Planchamp and C. Sessa and A. Fagotti",

note = "Publisher Copyright: {\textcopyright} 2024 European Society for Medical Oncology, European Society of Gynecological Oncology, European Society of Pathology",

year = "2024",

month = mar,

day = "1",

doi = "10.1016/j.annonc.2023.11.015",

language = "English",

volume = "35",

pages = "248--266",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "3",

}

Ledermann, JA, Matias-Guiu, X, Amant, F, Concin, N, Davidson, B, Fotopoulou, C, González-Martin, A, Gourley, C, Leary, A, Lorusso, D, Banerjee, S, Chiva, L, Cibula, D, Colombo, N, Croce, S, Eriksson, AG, Falandry, C, Fischerova, D, Harter, P, Joly, F, Lazaro, C, Lok, C, Mahner, S, Marmé, F, Marth, C, McCluggage, WG, McNeish, IA, Morice, P, Nicum, S, Oaknin, A, Pérez-Fidalgo, JA, Pignata, S, Ramirez, PT, Ray-Coquard, I, Romero, I, Scambia, G, Sehouli, J, Shapira-Frommer, R, Sundar, S, Tan, DSP, Taskiran, C, van Driel, WJ, Vergote, I, Planchamp, F, Sessa, C & Fagotti, A 2024, 'ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease', Annals of Oncology, VOL. 35, Numéro 3, p. 248-266. https://doi.org/10.1016/j.annonc.2023.11.015

TY - JOUR

T1 - ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer

T2 - pathology and molecular biology and early, advanced and recurrent disease

AU - Ledermann, J. A.

AU - Matias-Guiu, X.

AU - Amant, F.

AU - Concin, N.

AU - Davidson, B.

AU - Fotopoulou, C.

AU - González-Martin, A.

AU - Gourley, C.

AU - Leary, A.

AU - Lorusso, D.

AU - Banerjee, S.

AU - Chiva, L.

AU - Cibula, D.

AU - Colombo, N.

AU - Croce, S.

AU - Eriksson, A. G.

AU - Falandry, C.

AU - Fischerova, D.

AU - Harter, P.

AU - Joly, F.

AU - Lazaro, C.

AU - Lok, C.

AU - Mahner, S.

AU - Marmé, F.

AU - Marth, C.

AU - McCluggage, W. G.

AU - McNeish, I. A.

AU - Morice, P.

AU - Nicum, S.

AU - Oaknin, A.

AU - Pérez-Fidalgo, J. A.

AU - Pignata, S.

AU - Ramirez, P. T.

AU - Ray-Coquard, I.

AU - Romero, I.

AU - Scambia, G.

AU - Sehouli, J.

AU - Shapira-Frommer, R.

AU - Sundar, S.

AU - Tan, D. S.P.

AU - Taskiran, C.

AU - van Driel, W. J.

AU - Vergote, I.

AU - Planchamp, F.

AU - Sessa, C.

AU - Fagotti, A.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

AB - The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

KW - chemotherapy

KW - maintenance treatment

KW - molecular biology

KW - ovarian cancer

KW - pathology

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85185824944&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2023.11.015

DO - 10.1016/j.annonc.2023.11.015

M3 - Article

C2 - 38307807

AN - SCOPUS:85185824944

SN - 0923-7534

VL - 35

SP - 248

EP - 266

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -